Send to

Choose Destination
Adv Pharmacol. 2012;64:177-212. doi: 10.1016/B978-0-12-394816-8.00006-4.

scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease.

Author information

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.


Preclinical development of scyllo-inositol for the treatment of Alzheimer's disease (AD) has been investigated in both in vitro and in vivo models with positive results. scyllo-Inositol stabilized a small conformer of Aβ42 in vitro, neutralized cell derived Aβ trimers and promoted low molecular weight Aβ species in vivo. These interactions resulted in decreased neuronal toxicity, increased long-term potentiation (LTP) and ablation of cognitive deficits in multiple mouse models of AD. scyllo-Inositol bioavailability, pharmacokinetics, and small animal toxicology studies demonstrated the potential for translation to human patients. The results of Phase I and Phase II clinical trials for AD are presented. Furthermore, the use of this compound for imaging and other amyloid related disorders is discussed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center